{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vaccine+therapy&page=2",
    "query": {
      "intervention": "vaccine therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 4303,
    "total_pages": 431,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vaccine+therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vaccine+therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T04:06:32.257Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02473510",
      "title": "Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 301,
      "start_date": "2015-06",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 3,
      "location_summary": "South Miami, Florida • Stockbridge, Georgia • Portland, Oregon",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473510"
    },
    {
      "nct_id": "NCT07249320",
      "title": "Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "ABRYSVO",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2025-12-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07249320"
    },
    {
      "nct_id": "NCT00445523",
      "title": "Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "TroVax® (Immunological Vaccine Therapy)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interferon-alpha",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2006-05",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2016-03-17",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445523"
    },
    {
      "nct_id": "NCT03999996",
      "title": "Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "63 Years",
        "sex": "ALL",
        "summary": "13 Years to 63 Years"
      },
      "enrollment_count": 365,
      "start_date": "2019-11-12",
      "completion_date": "2024-05-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 8,
      "location_summary": "Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Richfield",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03999996"
    },
    {
      "nct_id": "NCT04084769",
      "title": "Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Immunisation (Healthy Volunteers)"
      ],
      "interventions": [
        {
          "name": "Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal Group B vaccine (Trumenba®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal group B vaccine (Bexsero®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "13 Years to 26 Years"
      },
      "enrollment_count": 570,
      "start_date": "2019-09-03",
      "completion_date": "2020-09-14",
      "has_results": true,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Bridgeton",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084769"
    },
    {
      "nct_id": "NCT00674791",
      "title": "Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "OCPM Immunotherapeutic Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2007-06",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2013-06-19",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00674791"
    },
    {
      "nct_id": "NCT04368988",
      "title": "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 rS - Phase 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution (NSS), Placebo - Phase 1",
          "type": "OTHER"
        },
        {
          "name": "Normal saline solution (NSS), Placebo - Phase 2",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline solution (NSS), Placebo, Day 21 - Phase 1",
          "type": "OTHER"
        },
        {
          "name": "SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 1419,
      "start_date": "2020-05-25",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 8,
      "location_summary": "Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more",
      "locations": [
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04368988"
    },
    {
      "nct_id": "NCT00346073",
      "title": "Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acellular Pertussis",
        "Diphtheria",
        "Tetanus"
      ],
      "interventions": [
        {
          "name": "Boostrix™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ADACEL®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "19 Years to 64 Years"
      },
      "enrollment_count": 2337,
      "start_date": "2006-07-13",
      "completion_date": "2007-03-07",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 42,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00346073"
    },
    {
      "nct_id": "NCT00584454",
      "title": "Safety Evaluation of a Q-fever Vaccine, NDBR 105",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Q Fever"
      ],
      "interventions": [
        {
          "name": "Q Fever Vaccine (NDBR 105",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2006-02",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2020-01-03",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 1,
      "location_summary": "Fort Deterick, Maryland",
      "locations": [
        {
          "city": "Fort Deterick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00584454"
    },
    {
      "nct_id": "NCT02231866",
      "title": "Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Immune Responses to Vaccine"
      ],
      "interventions": [
        {
          "name": "VRC-EBOADC069-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-EBOADC076-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 143,
      "start_date": "2014-08-27",
      "completion_date": "2017-04-05",
      "has_results": false,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-09-30T04:06:32.257Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231866"
    }
  ]
}